Esophageal Cancer | Topics

 
Early Vs Delayed Surgery Associated With Improved Survival in Stage II/III Esophageal Cancer
May 13, 2022

Although patients with stage I esophageal cancer who received early surgery had similar survival vs delayed surgery, those with stage II and III disease experienced improved outcomes.

First-Line Tislelizumab and Chemotherapy Combo Significantly Improves OS for Advanced Esophageal Cancer
April 28, 2022

Investigators reported positive topline findings from the phase 3 RATIONALE 306 trial, assessing the first-line combination of tislelizumab and chemotherapy in previously untreated unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

First-Line Nivolumab Combos Yield Improved OS Vs Chemo Alone in Esophageal Cancer
February 22, 2022

The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.

Biologics License Applications Accepted for Nivolumab/Ipilimumab and Nivolumab/Chemo for Unresectable Advanced ESCC
October 04, 2021

Treatment with nivolumab/ipilimumab and nivolumab/chemotherapy has demonstrated efficacy in unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, with results from the CheckMate-648 trial leading to the acceptance of the regimens’ applications by the FDA.

Pembrolizumab Plus Chemotherapy Combination Improves Survival in Esophageal Squamous Cell Carcinoma
September 21, 2021

Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.

Patients With Frontline Gastric/GEJ Cancers Benefit When Nivolumab Is Added to Chemotherapy
September 19, 2021

Data presented at 2021 ESMO show that nivolumab plus chemotherapy improves survival outcomes in certain patients with frontline gastrointestinal cancers, but not nivolumab plus ipilimumab.

Patients With Esophageal Squamous Cell Carcinoma Treated With Frontline Toripalimab Plus Chemo Derive Survival Benefit
September 18, 2021

Results from the phase 3 JUPITER06 trial demonstrated positive outcomes with toripalimab plus platinum-based chemotherapy in patients with treatment-naïve advanced or metastatic esophageal squamous cell carcinoma.

Patients with Advanced Esophageal Cancers Benefit From Addition of Sintilimab
September 17, 2021

Results of 2 studies presented at 2021 ESMO demonstrate superior efficacy of sintilimab plus chemotherapy versus chemotherapy alone in certain gastrointestinal cancers.

Tiragolumab/Atezolizumab Demonstrate Promising Preliminary Activity in Metastatic Esophageal Cancer
July 12, 2021

Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer.

Nivolumab Combinations Superior to Chemotherapy Alone for Metastatic Esophageal Cancer
June 03, 2021

Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma